Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21085013 | 0.93 | ESR2 (0.31) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4069123 | 0.82 | — | — | |
| SCHEMBL10772436 | 0.82 | SIGMAR1 (0.39) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL330353 | 0.82 | — | — | |
| SCHEMBL330197 | 0.79 | SIGMAR1 (0.42) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL9154269 | 0.79 | SIGMAR1 (0.42) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL18421980 | 0.79 | SIGMAR1 (0.37) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL11880727 | 0.79 | SIGMAR1 (0.42) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1534917 | 0.79 | SIGMAR1 (0.42) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL11691906 | 0.79 | SIGMAR1 (0.42) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | GPR119, IAPP, DPP4 | SIGMAR1 3095/4885CHRM2 2831/4885CHRM4 2771/4885 |
| US-10759749-B2 | Therapeutic agent for diabetes | GPR119, IAPP, DPP4 | SIGMAR1 2853/4885CHRM2 2729/4885CHRM4 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.